Mechanism of Jiming Powder in ameliorating heart failure with preserved ejection fraction based on metabolomics.
10.19540/j.cnki.cjcmm.20230510.702
- Author:
Xiao-Qi WEI
1
;
Xin-Yi FAN
1
;
Hai-Yin PU
1
;
Shuai LI
1
;
Jia-Yang TANG
1
;
Kuo GAO
1
;
Fang-He LI
1
;
Xue YU
1
;
Shu-Zhen GUO
1
Author Information
1. School of Traditional Chinese Medicine, Beijing University of Chinese Medicine Beijing 100029, China.
- Publication Type:Journal Article
- Keywords:
Jiming Powder;
heart failure with preserved ejection fraction;
hypertension;
metabolomics;
obesity
- MeSH:
Male;
Mice;
Animals;
Heart Failure/metabolism*;
Powders;
Stroke Volume/physiology*;
Chromatography, Liquid;
NG-Nitroarginine Methyl Ester/therapeutic use*;
Mice, Inbred C57BL;
Tandem Mass Spectrometry;
Metabolomics;
Biomarkers;
Water
- From:
China Journal of Chinese Materia Medica
2023;48(17):4747-4760
- CountryChina
- Language:Chinese
-
Abstract:
In this study, untargeted metabolomics was conducted using the liquid chromatography-tandem mass spectrometry(LC-MS/MS) technique to analyze the potential biomarkers in the plasma of mice with heart failure with preserved ejection fraction(HFpEF) induced by a high-fat diet(HFD) and nitric oxide synthase inhibitor(Nω-nitro-L-arginine methyl ester hydrochloride, L-NAME) and explore the pharmacological effects and mechanism of Jiming Powder in improving HFpEF. Male C57BL/6N mice aged eight weeks were randomly assigned to a control group, a model group, an empagliflozin(10 mg·kg~(-1)·d~(-1)) group, and high-and low-dose Jiming Powder(14.3 and 7.15 g·kg~(-1)·d~(-1)) groups. Mice in the control group were fed on a low-fat diet, and mice in the model group and groups with drug intervention were fed on a high-fat diet. All mice had free access to water, with water in the model group and Jiming Powder groups being supplemented with L-NAME(0.5 g·L~(-1)). Drugs were administered on the first day of modeling, and 15 weeks later, blood pressure and cardiac function of the mice in each group were measured. Heart tissues were collected for hematoxylin-eosin(HE) staining to observe pathological changes and Masson's staining to observe myocardial collagen deposition. Untargeted metabolomics analysis was performed on the plasma collected from mice in each group, and metabolic pathway analysis was conducted using MetaboAnalyst 5.0. The results showed that the blood pressure was significantly lower and the myocardial concentric hypertrophy and left ventricular diastolic dysfunction were significantly improved in both the high-dose and low-dose Jiming Powder groups as compared with those in the model group. HE and Masson staining showed that both high-dose and low-dose Jiming Powder significantly alleviated myocardial fibrosis. In the metabolomics experiment, 23 potential biomarkers were identified and eight strongly correlated metabolic pathways were enriched, including linoleic acid metabolism, histidine metabolism, alpha-linolenic acid metabolism, glycerophospholipid metabolism, purine metabolism, porphyrin and chlorophyll metabolism, arachidonic acid metabolism, and pyrimidine metabolism. The study confirmed the pharmacological effects of Jiming Powder in lowering blood pressure and ameliorating HFpEF and revealed the mechanism of Jiming Powder using the metabolomics technique, providing experimental evidence for the clinical application of Jiming Powder in treating HFpEF and a new perspective for advancing and developing TCM therapy for HFpEF.
